Best in Biotech 21 Mar 2023 5 advancements in Down syndrome research over the past year …studies have shown that people with Down syndrome have a hyperactivated CB1 cannabinoid receptor, the drug candidate is based on the modulation of the receptor with specific inhibitors which has… March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Startup Scout 31 Jan 2020 This Cancer Immunotherapy Attacks the Sugar Coat of Tumor Cells …that are investigating glycans as a brand new target for cancer immunotherapies. CellmAbs’ lead candidate is an antibody drug designed to block aberrant glycans on cancer cells. Blocking these aberrant… January 31, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline …decline, respectively. The incidence of amyloid-related imaging abnormalities (ARIA) was consistent with the TRAILBLAZER-ALZ phase 2 study. ARIA is observed with the amyloid plaque clearing antibody class of therapies and… May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing …provide the contours of what might be possible: sustained antibody responses and LDL-lowering signals in preclinical models and non-human primates, with modest human signals so far for AT04A and ongoing… October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Feb 2020 This Startup is Developing Anti-Aging Antibodies The Heidelberg-based startup Velabs Therapeutics aims to make anti-aging drugs that selectively destroy ‘aged’ cells in the body. Mission: To develop antibody drugs using microfluidics technology that can kill old… February 21, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2024 From consumer health to pure biopharma: Inside Sanofi’s strategic shift …as ANB033 (anti-CD122 antagonist antibody) entering a phase 1 trial, and ANB101 (BDCA2 modulator antibody) in preclinical development. Moreover, just after it announced it wanted to separate its consumer health… November 5, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 11 Nov 2019 Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II …bone disease. Mereo tested different doses of its antibody drug in 112 adults with osteogenesis imperfecta in a 12-month phase IIb trial. The drug failed to meet the main endpoint… November 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Disc Medicine raises $62.5M for hematology programs …DISC-0974 (hepcidin suppression) is another treatment in the pipeline. It is a first-in-class, investigational, anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin production and increase serum iron to enable erythropoiesis…. February 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 27 Mar 2017 Meet one of the Most Successful Biotech Entrepreneurs in the UK …Molecular Genetics at Leicester, and then a postdoc at Bath on antibody engineering, before moving to Cambridge to work at the GURDON Institute. It was during his postdoc and his… March 27, 2017 - 7 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders …Maraganore, chair of Hemab’s board of directors. About HMB-001 HMB-001 is bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets… February 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2016 ‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis. Sad news for Novartis and… April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 Affibody and Chiesi Group to develop treatments for respiratory diseases …commercial milestone payments up to $637 million plus mid-single to low double-digit royalties on sales. About Affibody molecules Affibody molecules are a novel class of antibody mimetics with characteristics surpassing… March 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email